The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Methods Matter -- Standard Production Platforms for Recombinant AAV Produce Chemically and Functionally Distinct Vectors
Open accessPreprint — published as 10.1016/j.omtm.2020.05.018
Abstract
Different manufacturing approaches have been used in the production of recombinant adeno-associated virus (rAAV). The two leading approaches are transiently transfected human HEK293 cells and live baculovirus infection of Sf9 insect cells. Unexplained differences in vector performance have been seen clinically and preclinically. Thus, we performed for the first time a highly controlled comparative production analysis varying only the host cell species but keeping all other rAAV production parameters the same. We demonstrate that host cell species is critical for determining vector potency. Given these key findings, we then sought to deeply characterize differences in rAAVs when produced by these two manufacturing platforms with multiple analytical approaches including: proteomic profiling by mass spectrometry, isoelectric focusing, cryo-EM, denaturation assays, genomic and epigenomic sequencing of packaged genomes, human cytokine profiling, and comparative functional transduction assessments in vitro and in vivo , including in humanized liver mice. Using these tools we’ve made two major discoveries: 1) rAAV capsids have post-translational modifications (PTMs) including glycosylation, acetylation, phosphorylation, methylation and deamidation, and these PTMs differ between platforms; 2) rAAV genomes are methylated during production, and these methylation marks are also differentially deposited between platforms. In addition, our data also demonstrate that host cell protein impurities differ between platforms and can have their own PTMs including potentially immunogenic N-linked glycans. We show that human-produced rAAVs are more potent than baculovirus- Sf9 vectors in various cell types in vitro ( P < 0.05-0.0001), in various mouse tissues in vivo ( P < 0.03-0.0001), and in human liver in vivo ( P < 0.005). Collectively, our findings were reproducible across vendors, including commercial manufacturers, academic core facilities, and individual laboratory preparations. These vector differences may have clinical implications for rAAV receptor binding, trafficking, expression kinetics, expression durability, vector immunogenicity as well as cost considerations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 3 Packaged rAAV Genomes Are Methylated during Production and Differentially Methylated Based on the Manufacturing Platform The five tracks of the Circos plot from the outside-in represent the following. First, a schematic of the ssAAV8 genome sequenced with key features labeled is shown (inverted terminal repeat [ITR], orange; intervening sequences, gray; EF1α promoter, red; firefly luciferase expression cassette, blue; woodchuck hepatitis virus posttranscriptional regulatory element [WPRE], plum; human growth hormone polyadenylation signal [hGHpA], magenta). Second, in blue, the methylation ratios for all detected sites for baculovirus-Sf9-produced rAAV8 are shown; the plotting represents a minimum of 0 and a maximum of 1 in 0.1 increments. Third, in red, the methylation ratios for all detected sites for human-produced rAAV are shown; scale same as previous. Fourth, in blue, the total numbers of reads at detected sites for baculovirus-Sf9 produced rAAV8 are shown; in log2 scale, from a minimum of 0 (total reads of 1) to a maximum of 11 (total reads of 211), in 0.1 increments. Fifth, in red, the total numbers of reads at detected sites for human-produced rAAV are shown; scale same as previous. The three sites with statistically significant differential methylation are highlighted in green (C:1208, C:2970, C:3779).](https://figures.cochat.ai/paper-figures/78bbfdddd3c14dd6ad0c41c22c28e3ac/methods-matter-standard-production-platforms-for-recombinant-aav-produce-figure-3.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“It showed that the rAAV capsids can have post-translational modifications, such as glycosylation, that depend on the species origin of the production cell.”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [44]
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, rAAVs produced in a human cell line (HEK293T) compared to baculovirus-Sf9 produced rAAVs were more potent in transfecting the liver in mice in vivo and in vitro (HEK293T, Huh7, human induced Pluripotent Stem Cells (hiPSCs), primary human fibroblasts, mouse C2C12 cells).”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [44]
The cited source says what the claim attributes to it.
In the citing paper
“The rAAV production cell line and production cell line related impurities can influence the transduction efficiency in target tissue [44] (Sections 2 and 4.4).”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Trimmomatic: a flexible trimmer for Illumina sequence data
Bolger, A. M., Lohse, M., & Usadel, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu170 · Cited by 65,548
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895
Circos: An information aesthetic for comparative genomics
Krzywinski, M., Schein, J., Birol, İ., Connors, J., Gascoyne, R., Horsman, D., Jones, S. J., & Marra, M. A. (2009) · Genome Research · doi:10.1101/gr.092759.109 · Cited by 10,964
MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy
Zheng, S. Q., Palovcak, E., Armache, J.-P., Verba, K. A., Cheng, Y., & Agard, D. A. (2017) · Nature Methods · doi:10.1038/nmeth.4193 · Cited by 7,777
Functions of DNA methylation: islands, start sites, gene bodies and beyond
Jones, P. A. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3230 · Cited by 6,061
ImageJ2: ImageJ for the next generation of scientific image data
Rueden, C. T., Schindelin, J., Hiner, M. C., DeZonia, B. E., Walter, A. E., Arena, E. T., & Eliceiri, K. W. (2017) · BMC Bioinformatics · doi:10.1186/s12859-017-1934-z · Cited by 5,980
Elias, J. E., & Gygi, S. P. (2007) · Nature Methods · doi:10.1038/nmeth1019 · Cited by 3,925
Research works printed but not linked: 3
- https://investors.biomarin.com/2019-01-07-BioMarin-Highlights-Key-Milestones-for-2019-at-37th-Annual-J-P-Morgan-Healthcare-Conference-in-San-Francisco.
- https://www.pfizer.com/news/press-release/press-release-detail/sangamo_and_pfizer_announce_phase_1_2_interim_data_for_investigational_hemophilia_a_gene_therapy.
- 2013, Phenix.real_space_refine, Computational Crystallography Newsletter, 4, 43
Cited by
Viral vector platforms within the gene therapy landscape
Bulcha, J. T., Wang, Y., Ma, H., Tai, P. W. L., & Gao, G. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00487-6 · Cited by 1,404
AAV vectors: The Rubik’s cube of human gene therapy
Pupo, A., Fernández, A., Low, S. H., François, A., Suárez-Amarán, L., & Samulski, R. J. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.09.015 · Cited by 360
HEK293 Cell Line as a Platform to Produce Recombinant Proteins and Viral Vectors
Tan, E., Chin, C. S. H., Lim, Z. F. S., & Ng, S. K. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.796991 · Cited by 251
Bucher, K., Rodríguez-Bocanegra, E., Dauletbekov, D., & Fischer, M. D. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100915 · Cited by 242
Overcoming innate immune barriers that impede AAV gene therapy vectors
Muhuri, M., Maeda, Y., Ma, H., Ram, S., Fitzgerald, K. A., Tai, P. W. L., & Gao, G. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143780 · Cited by 212
Metadata
- Authors
- Rumachik, N. G., Malaker, S. A., Poweleit, N., Maynard, L. H., Adams, C. M., Leib, R. D., Cirolia, G., Thomas, D., Stamnes, S., Holt, K., Sinn, P., May, A. P., & Paulk, N. K.
- Affiliations
- Stanford University (US)
- University of California, San Francisco (US)
- Chan Zuckerberg Biohub San Francisco (US)
- Cold Spring Harbor Laboratory (US)
- University of Iowa (US)
- Corresponding author
- Paulk, Nicole K.
- ORCID
- Venue
- Molecular Therapy — Methods & Clinical Development
- Publisher
- openRxiv
- Published
- 2019-05-17
- Volume
- 18
- Pages
- 98-118
- ISSN
- 2329-0501 (ISSN-L)
- PMC
- PMC7488757
- OpenAlex
- W3026609212
- Cited by
- 156
- References
- 71
- Citations by year
- 2026: 15 · 2025: 31 · 2024: 27 · 2023: 28 · 2022: 24 · 2021: 23 · 2020: 7 · 2019: 1
- FWCI
- 12.02
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Molecular Therapy — Methods & Clinical Development (publishedVersion, cc-by-nc-nd)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Howard Hughes Medical Institute
- Children's Hospital of Philadelphia
- University of Georgia
- National Institutes of Health (1s10od010786-01, HL51670, CA086862, DK54759)
- University of California, Davis
- University of California, San Francisco
- Holden Comprehensive Cancer Center, University of Iowa (P30-CA086862)
- National Heart, Lung, and Blood Institute (P01HL051670, U01HL145795, P01HL089707)
- National Cancer Institute (U01CA207702, P30CA086862)
- National Institute of General Medical Sciences (F32GM126663)
- National Institute of Allergy and Infectious Diseases (T32AI060537)
- National Institute of Diabetes and Digestive and Kidney Diseases (K01DK107607, P30DK054759)
- National Institute of Environmental Health Sciences (U01ES032673)
- Genome Center, University of California, Davis (1S10OD010786-01)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- recombinant adeno-associated virus, transient transfection, post-translational modification, DNA methylation, vector immunogenicity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.